Document is current
Any future updates will be listed below
-
Authors
Greene, Adina
Ho, Andy
Amjad, Sarah
Butterfield, Richard J.
Zhang, Nan
Mangold, Aaron R.
Costello, Collin M.
-
Funding
Funding for this research was provided by:
Melanoma Research Alliance
Kemper and Ethel Marley Foundation Endowment.
- License Information
-
More Information
Article History
Received: 1 October 2024
Revised: 10 October 2024
Accepted: 26 November 2024
First Online: 14 December 2024
Declarations
:
: Not applicable.
: The authors declare no competing interests.
: No relevant disclosures. Unrelated to this study, he is an investigator for DeepX Health and Merck.
: No relevant disclosures. He has consulted for Kyowa, Eli Lilly, Momenta, UCB, and Regeneron in the past, greater than 24 months ago. He has consulted for PHELEC in the past, great than 12 months. He has consulted for Incyte, Soligenix, Clarivate, and Bristol Myers Squibb in the past, less than 12 months ago. He consults for Argenyx, Boehringer, Janssen, and Ingelheim currently. He consults for Regeneron and Pfizer currently with payments to the institution. He has grant support from Kyowa, Miragen, Regeneron, Corbus, Pfizer, Incyte, Eli Lilly, Aregenx, Palbella, Abbvie, Priovant, Merck in the last 24 months. Beyond 24 months, grant support has come from Sun Pharma, Elorac, Novartis, and Janssen. His current patents include Methods and Materials for assessing and treating cutaneous squamous cell carcinoma (provisional 63-423254), use of oral JAKi in Lichen Planus (provisional 63/453,065), and Topical Ruxolitinib in Lichen Planus (WO2022072814A1).
